<DOC>
	<DOCNO>NCT01591200</DOCNO>
	<brief_summary>This study evaluate safety efficacy mesenchymal stem cell patient cirrhosis liver . Stem cell inject hepatic artery . Improvement various parameter observe 2 year .</brief_summary>
	<brief_title>Dose Finding Study Assess Safety Efficacy Stem Cells Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Alcoholic</mesh_term>
	<criteria>Alcoholic cirrhotics 1865 year age ( diagnosed clinical , biochemical , sonographic , radiological [ CT scan ] histological evidence cirrhosis portal hypertension ) . Evidence decompensated liver disease screening ( e.g . Child class B C , ChildPugh score â‰¥7 &lt; 14 ) . MELD score least 10 ( UNOS Meld calculator ) . Normal AFP Level Hb &gt; 10gm/dl . Female patient childbearing age must willing use accept method contraception course study Signed informed consent . Patients likely undergo liver transplantation duration study . Presence advance hepatic encephalopathy Grades 3 &amp; 4 ( West Haven criterion grade hepatic encephalopathy ) time screen Active variceal bleed . Refractory ascites . Evidences autoimmune liver disease ANA AntiLKM positivity . Platelet count &lt; 30,000/mm3 . Serum Sodium &lt; 129mEq/L . Serum Creatinine &gt; 2 mg/dl . Hepatocellular carcinoma malignancy Active infectious disease . Presence severe underlie cardiac , pulmonary renal disease . Excessive alcohol ( &gt; 30 gm alcohol/day ) use last 3 month screen . Positive HbSAg antibody HIV HCV . Pregnancy lactation . Participation clinical trial . Unwilling/unable sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Alcoholic</keyword>
	<keyword>Liver</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Stem</keyword>
	<keyword>Cells</keyword>
</DOC>